Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco NASDAQ 100 ETF (QQQM) vs Smith & Nephew plc (SNN) Price & Performance

Invesco NASDAQ 100 ETFTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Invesco NASDAQ 100 ETF vs Smith & Nephew plc — how do they compare? Invesco NASDAQ 100 ETF trades at $309.49 (market cap $113.40B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 10.2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and Smith & Nephew plc for 121 Days on average.

QQQMSNN
Market Cap
$113.40B$11.10B
Volume
2,866,2361,051,703
Sector
Broad Market / FactorHealth
52-Week High
$312.76$37.17
52-Week Low
$229.87$26.42
Typical Hold Time
54 Days121 Days
Enterprise Value
—$14.13B
Dividend Yield
—2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco NASDAQ 100 ETF

QQQM (Invesco NASDAQ 100 ETF) trades at $309.27, down 0.88% on the day, with a bullish technical signal from moving averages. The ETF tracks the NASDAQ-100 index with a low 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026. Technical indicators show support at $305 and resistance at $311, with neutral oscillator readings suggesting balanced momentum.

The outlook remains positive given the NASDAQ-100's growth exposure and cost efficiency versus QQQ. Risks include market concentration in technology stocks and potential volatility from macroeconomic factors. Institutional accumulation and favorable expense structure support long-term positioning, though investors should monitor index composition changes and broader market trends.

Smith & Nephew plc

Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.

The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QQQM
95% Buy5% Sell
Avg holding period · 54 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.

Read more on QQQM →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →